Module Title

ICBI’s vision is to unlock pathways to deliver diagnostic and curative treatments for patients afflicted with neuro-degenerative Alzheimer's and Parkinson's diseases. These diseases cannot be treated by current conventional drugs because they are blocked by the blood-brain barrier. Our technology simultaneously binds to multiple disease-specific biomarkers to target pathological lesions in the brain and to trigger a disease-modifying response. Our company is developing biologics that specifically target pathologic proteins, thus offering clinical potential for early diagnosis, monitoring disease progression, and increased therapeutic efficacy of drugs.